Abstract
Pitavastatin is a synthetic 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor, which was approved for the primary treatment of hypercholesterolemia and combined dyslipidemia since 2009. Today, in vitro and in vivo studies have shown pitavastatin as a potentially effective therapeutic agent for different cancers, including; liver, ovarian, breast, skin, and intestinal cancers. These studies have evaluated pitavastatin both as a single treatment and in combination with other therapeutic options. This chapter focuses on the potential anti-cancer effects of pitavastatin, including its mechanism of action as well as the potential adverse reactions linked to its clinical use.
Keywords: Anti-cancer, Anti-inflammatory, Apoptosis, Autophagy, Cell cycle arrest, Pitavastatin.
About this chapter
Cite this chapter as:
Saeb Aliwaini ;Pitavastatin and Cancer: Current and Future Prospects, Frontiers in Clinical Drug Research - Anti-Cancer Agents (2021) 7: 132. https://doi.org/10.2174/9781681087757121070006
DOI https://doi.org/10.2174/9781681087757121070006 |
Print ISSN 2451-8905 |
Publisher Name Bentham Science Publisher |
Online ISSN 2215-0803 |